When compared with the gene expression profile previous described, [17] the afatinib, neratinib and traztuzumab profiles exhibited similar trends in the differential expression of RB1CC1, FOXO3A, NR3C1, ERBB3 and CCND1 following a 12 hour exposure with 150 nM in the three breast cancer cell lines tested; BT474, SKBR3 and MDAMB453, while no such correlation was evident with treatment by the EGFR-targeting agent, gefitinib or that with BCR/ABL and Src inhibitor, dasatinib, or the anthracycline cytotoxic agent, epirubicin. Here, ERBB3 is linked to breast carcinoma.